Introduction {#s1}
============

Patients with haematological malignancies are reported to be less likely to receive input from specialist palliative care (SPC) or hospice services than those with other cancers.[@R1] [@R2] These diseases are associated with uncertainty about when SPC referrals should be made[@R3]; and they have significantly shorter intervals between referral and death compared to other cancers.[@R4] [@R5] Patients with haematological malignancies are also more likely to die in hospital[@R6]^--^[@R8]; a finding that is consistent across the disease spectrum despite the very diverse individual diagnostic subtypes.[@R9] Although an evidence base is beginning to emerge about these differences, explanations are still largely based on speculation and anecdote. In the UK, the Department of Health acknowledges the challenges associated with the delivery of end-of-life and palliative care in patients with haematological cancers, and in 2003, published guidance recommending further integration between clinical haematology and SPC services.[@R10]

Haematological malignancies are common, representing 1 in 10 of all cancers in the developed world.[@R11] [@R12] They are complex diseases, ranging from those that are acute in onset and often associated with poor survival, such as acute myeloid leukaemia (AML); to those that often follow a pathway of care closer to chronic disease than malignancy, such as myeloma. Treatments vary markedly and may include a 'watch and wait' approach to care (where the patient is actively monitored and only treated at the time of disease progression, or when they become particularly symptomatic), intensive or non-intensive chemotherapy, radiotherapy, bone marrow transplantation or antibody therapy. Many patients also receive supportive care (particularly blood products), which may be delivered alone or in combination with other treatments. Surgery is rarely a curative option in these diseases, although it may be used, for example, to stabilise fractures caused by bone disease in patients with myeloma. Finally, multiple lines of chemotherapy treatment may be given, particularly for the diseases that follow a continuous remitting/relapsing course.

Treatment may be given with curative intent, life-prolonging intent (for diseases, such as myeloma which is generally considered incurable at diagnosis), or for disease and symptom control. In this respect, the definition of 'palliative care' and the 'transition' from an active, life prolonging to a palliative approach to care -- which is recognised as being complicated generally[@R13] [@R14]--is particularly complex in these diseases. Additionally, the symptom burden associated with haematological malignancies is considered comparable to that of other cancers, with physical symptoms including fatigue, fever, bleeding, drowsiness, oral stomatitis and pain; and psychological symptoms including adjustment disorder, mood disorder and anxiety.[@R15]^--^[@R20] These problems arise due to both the disease processes and associated complications, as well as the side-effects and toxicities of treatments.[@R21] No correlation has been reported between the presence of symptoms and the likelihood of access to SPC services as a consequence of these.[@R19] [@R22]

There is little existing evidence about the factors determining differences in end-of-life care in patients with haematological cancers. This potentially inhibits identification of changes that could be introduced to ensure that patients receive the most appropriate and timely care, in a place of their choosing. Built on the pre-existing infrastructure of an established population-based patient cohort, the current research programme was instigated to address these issues. Our overarching aim was to develop and implement a methodology to capture detailed information about the care pathways (providers/settings) and transitions (curative/life-prolonging and palliative) of patients with specific haematological malignancies, during the period of time between diagnosis and death. The current paper describes the methodology, presents an overview of the dataset, and examines variations in SPC referral by age, sex, diagnostic sub-type, time from diagnosis to death, and place of death.

Methods {#s2}
=======

This programme of work was conducted within the existing framework of the Haematological Malignancy Research Network (<http://www.HMRN.org>), an on-going patient cohort covering a population of 3.6 million (\>2000 newly diagnosed haematological malignancies each year) that is broadly representative of the UK as a whole.[@R23] [@R24] Established in 2004, HMRN is a collaboration between a clinical haematology network, researchers at the University of York and the Haematological Malignancy Diagnostic Service (<http://www.HMDS.info>), which diagnoses all haematological malignancies in the area coding to the latest WHO classification scheme (currently ICD-O-3).[@R25] HMRN operates with Section 251 support under the National Health Service (NHS) Act 2006, enabling the Health and Social Care Information Centre (HSCIC) to provide us with nationwide information on deaths, subsequent cancer registrations, and Hospital Episode Statistics (HES). Additionally, all patients have full treatment, response and outcome data abstracted from their medical records by trained nurses operating to clinical trial standards.

Within HMRN, patients with haematological malignancies are treated at 14 hospitals. For the current study, we identified all patients newly diagnosed with AML, diffuse large B-cell lymphoma (DLBCL) and myeloma between 1 May 2005 and 30 April 2008, who received their first treatment at one of two large teaching hospitals, and were deceased by 30 April 2010 (reflecting a minimum of 2 years and maximum of 5 years follow-up). Patients living in the catchment area of these two hospitals may access SPC services in the hospital (in-patient and out-patient) and/or the community setting; and hospice care is also available.

For this project, HMRN\'s routinely collected data were supplemented by more detailed information abstracted from hospital records and community SPC records, using a day-by-day calendar approach spanning the entire time from diagnosis to death. This included details of all specific hospital events (out-patient appointments, in-patient episodes, medical specialities managing care and clinical decisions); SPC contacts (referrals to the hospital and/or community teams, type and frequency of contact and input); and details of death (preferred and actual place of care and death). [Figure 1](#BMJSPCARE2013000578F1){ref-type="fig"} summarises the data collection framework, with blue boxes indicating the routine data collection which takes place for all HMRN patients and green boxes showing the additional pathway data collected for patients in this study.

![Summary of data.](bmjspcare-2013-000578f01){#BMJSPCARE2013000578F1}

Data were entered into a calendar and event-based relational database, with each key event having the capacity to store information on multiple sub-events. This permitted information, such as in-patient episodes, to be recorded alongside the specialists providing care and other important sub-events including, for example, clinical decisions (such as transitions in care or resuscitation status). This enabled detailed patient-specific pathways to be constructed and manipulated to highlight specific events and activities of interest. Analyses were conducted with SAS (V.9.3),[@R26] and logistic regression was used to compare differences between patients who received SPC and those who did not.

Results {#s3}
=======

Of the 323 patients who were diagnosed and died during the study period, 107 (33.1%) had AML, 102 (31.6%) DLBCL and 114 (35.3%) had myeloma ([table 1](#BMJSPCARE2013000578TB1){ref-type="table"}). Overall, 155 (47.9%) had at least one SPC referral, and there were no differences between those that were referred and those that were not in terms of age or sex. Significant differences in referral patterns were evident, however, by disease sub-type; patients with myeloma being almost twice as likely to have an SPC referral (OR 1.96, CIs 1.15 to 3.35) as those with AML. The likelihood of referral also increased with longer survival; patients surviving 1 year and above, for example, were over six times more likely to be referred (OR 6.58, 95% CIs 3.32 to 13.03) than those dying within a month of diagnosis. Being referred to the SPC team was also significantly associated with place of death, and those dying at home were three times more likely to be referred to SPC services (OR 3.07, CIs 1.59 to 5.93) and those dying in a hospice almost five times more likely (OR 4.74, CIs 1.51 to 14.81) compared with those dying in hospital. Figure 1 Summary of data

###### 

Patient characteristics by SPC referral

  --------------------------------------------------------------------------------------------------------------
                                          Total\       No SPC referral\   SPC referral\   OR (95% CI)
                                          n (%)        n (%)              n (%)           
  --------------------------------------- ------------ ------------------ --------------- ----------------------
  Total                                   323 (100)    168 (100)          155 (100)       

  Sex                                                                                     

   Male                                   178 (55.1)   92 (54.8)          86 (55.5)       1

   Female                                 145 (44.9)   76 (45.2)          69 (44.5)       0.97 (0.63 to 1.51)

  Age, years                                                                              

   ≤60                                    58 (18.0)    28 (16.7)          30 (19.3)       1

   61--74                                 122 (37.8)   61 (36.3)          61 (39.4)       0.93 (0.50 to 1.74)

   75+                                    143 (44.2)   79 (47.0)          64 (41.3)       0.76 (0.41 to 1.34)

  Diagnosis                                                                               

   AML                                    107 (33.1)   61 (36.3)          46 (29.7)       1

   DLBCL                                  102 (31.6)   61 (36.3)          41 (26.4)       0.89 (0.51 to 1.55)

   Myeloma                                114 (35.3)   46 (27.4)          68 (43.9)       1.96 (1.15 to 3.35)

  Time from diagnosis to death (months)                                                   

   ≤1                                     75 (23.2)    59 (35.1)          16 (10.3)       1

   1--6                                   83 (25.7)    47 (28.0)          36 (23.2)       2.82 (1.40 to 5.70)

   6--12                                  62 (19.2)    25 (14.9)          37 (23.9)       5.46 (2.58 to 11.56)

   12+                                    103 (31.9)   37 (22.0)          66 (42.6)       6.58 (3.32 to 13.03)

  Place of death                                                                          

   Hospital                               240 (74.3)   138 (82.1)         102 (65.8)      1

   Home                                   49 (15.2)    15 (8.9)           34 (21.9)       3.07 (1.59 to 5.93)

   Hospice                                18 (5.6)     4 (2.4)            14 (9.0)        4.74 (1.51 to 14.81)

   Nursing home                           16 (4.9)     11 (6.6)           5 (3.2)         0.62 (0.21 to 1.83)
  --------------------------------------------------------------------------------------------------------------

AML, acute myeloid leukaemia; DLBCL, diffuse large B-cell lymphoma; SPC, specialist palliative care.

With respect to the type of SPC input, referral to the community team was slightly more common than referral to the hospital team, although we found that 62 (19.2%) patients received support from both hospital and community services ([table 2](#BMJSPCARE2013000578TB2){ref-type="table"}). Different referral practices were observed by diagnostic sub-type; patients with AML being more likely to be referred to the community than the hospital SPC team (37.4% and 19.6%, respectively). Myeloma patients were somewhat more likely to be referred to hospital than community services (46.5% compared with 41.2%, respectively), although a large proportion of these patients (28.1%) were referred to both services.

###### 

Type of SPC referral by diagnosis

                                     Type of SPC referral                
  --------- ----------- ------------ ---------------------- ------------ -----------
  Total     323 (100)   155 (47.9)   100 (31.0)             117 (36.2)   62 (19.2)
  AML       107 (100)   46 (43.0)    21 (19.6)              40 (37.4)    15 (14.0)
  DLBCL     102 (100)   41 (40.2)    26 (25.5)              30 (29.4)    15 (14.7)
  Myeloma   114 (100)   68 (59.6)    53 (46.5)              47 (41.2)    32 (28.1)

AML, acute myeloid leukaemia; DLBCL, diffuse large B-cell lymphoma; SPC, specialist palliative care.

Discussion {#s4}
==========

This is the first study to examine referral to SPC services in patients with AML, DLBCL and myeloma. Importantly, we found evidence of greater integration between clinical haematology teams and SPC services than expected, with almost half the patients having at least one referral. Variations with diagnosis were, however, observed, and patients with myeloma were more likely to be referred than those with AML or DLBCL. We found important variations in referral practices by duration of time from diagnosis to death, with the likelihood of referral increasing with longer survival. SPC referral was clearly associated with place of death, and those referred were less likely to die in hospital. Evidence of different types of SPC referral (to the hospital or community team) was also noted by diagnostic sub-type.

Strengths/weaknesses of study {#s4a}
-----------------------------

With more than 300 patients, our study is the largest in the UK and one of the largest in the world to examine SPC referrals specifically in patients with haematological cancers. Covering a population of 3.6 million, our patient cohort (HMRN) is generalisable to the UK, and provides a robust, well-established infrastructure for research.[@R23] [@R24] A major strength of HMRN is that all diagnoses are routinely coded to ICD-O-3,[@R25] meaning that we were able to examine variations between specific sub-types of haematological cancers, which is of particular importance given that these diseases can differ so markedly, with some being particularly indolent and others aggressive. This characteristic has an impact on the duration of survival, which is recognised as being associated with likelihood of SPC referral; longer survival equating to increased chance of referral.[@R27]^--^[@R30] The differences identified between the diseases included in this study demonstrate the importance of being able to examine specific sub-types in this way.

A further strength of our study is the enormous breadth and depth of data that were collected for each individual patient in the cohort. The complete treatment pathway from diagnosis to death was examined, therefore, encompassing hospital and community SPC input during this time. Data routinely collected on all HMRN patients to clinical trial standards formed the basis from which the treatment pathways were developed. These were supplemented by specific event-based information collected from detailed searching of numerous sources, including paper and computerised medical records. As a result of this multifaceted approach, we are extremely confident that the vast majority of SPC referrals were identified.

Although our on-going study may have raised awareness of the importance of integration between clinical haematology and SPC services in the study area, much of the data collection occurred retrospectively, and it is unlikely that this will have unduly influenced referral practices. The study was conducted in two large teaching hospitals, and while it is probable that there are some differences in practice in other geographical locations, we expect that our results are likely to be generally illustrative of other areas. One weakness of the study is that the maximum duration of the follow-up period was only 5 years. This means that the SPC contacts for myeloma and relapsed DLBCL may have been underestimated, although it is unlikely to have biased the results for AML, which is associated with particularly poor survival. Finally, as our study focused on specific haematological malignancies, we do not have comparators for other cancers (or indeed other haematological cancers), so cannot comment on relative differences between disease types.

Comparison with other studies {#s4b}
-----------------------------

A number of studies examining SPC referrals have included patients with haematological malignancies.[@R1] [@R22] [@R27]^--^[@R36] We observed much greater integration between clinical haematology and SPC services than was identified in the majority of these studies in the UK or elsewhere, and whether examining hospital or community referrals. The exception to this was a large Australian study.[@R28] It is difficult, however, to directly compare our findings with the results from existing studies, initially because of the use of widely varying methods of data collection, including interviews and questionnaires, as well as examination of medical records and database linkages, for example, to healthcare billing data. These studies have also examined involvement of SPC services in different settings (hospital or community), or with respect to specific services (such as Hospice at Home or Palliative Home Care), and some have also included only very small numbers of patients with haematological malignancies. Previously reported studies have not been able to categorise diseases as precisely as we have done and, instead, have defined 'haematological diseases' as a single group (including all leukaemias, lymphomas and myeloma), or have examined all types of lymphoma together and/or all types of leukaemia. More rarely, some specificity has been imposed by focussing on particular disease types, such as acute leukaemias. Finally, the situation is further complicated by the varied service provision inherent within and between countries, as well as different cultural practices.

Our results concur with other studies with respect to the association between longer survival and increasing likelihood of SPC referral,[@R27]^--^[@R30] and also the association between SPC referral and fewer hospital deaths for haematology patients and cancer patients in general.[@R28] [@R30] [@R35] [@R37]

Meaning of study: explanations and implications for clinicians and policy makers {#s4c}
--------------------------------------------------------------------------------

The differences we observed by diagnostic subgroup are comprehensible with respect to individual disease characteristics. Myeloma patients were referred more frequently to SPC services than patients with AML and DLBCL. By contrast with some of the other haematological malignancies, myeloma has many potential complications at diagnosis and relapse, including bone disease and fractures, severe and complex pain and renal failure. These problems often require support from a multidisciplinary team of clinicians with expertise in these areas. SPC practitioners are widely recognised and acknowledged for their skills in the management of complex issues such as these, particularly within the context of dealing with a new or relapsed cancer diagnosis, and many of the SPC referrals we identified were undoubtedly made in order to capitalise on these skills.[@R38] [@R39]

The high proportion of SPC referrals to community services in patients with AML may have occurred due to the lack of treatment options (beyond non-intensive chemotherapy and blood transfusions) available to older people with these diseases. This may mean that the terminal nature of the disease is recognised earlier in the care pathway (indeed at diagnosis), allowing community services to be put in place well in advance of the patient\'s deterioration. Further referrals across diseases are likely to have been made for a number of reasons, including: management of complex symptoms, such as the severe toxicity resulting from intensive treatment of AML in younger patients, or peripheral neuropathy, which is a common side effect of the chemotherapy used to treat myeloma and also lymphoma; provision of terminal care; and discussions about preferred place of care and death.

As mentioned above, SPC referrals may occur more often in patients who survive longer because there is adequate time to recognise that curative/life-prolonging treatment options are diminishing, and there is less chance of prolonged survival. The transition in this context is likely to occur over a period of time, rather than being associated with sudden deterioration and death. Furthermore, we noted fluctuations in SPC involvement over time, with services withdrawing as particular issues resolve, and then re-engaging later if new concerns arise. These multiple and often overlapping episodes also provided evidence of interservice referrals and activities between hospital and community teams.

SPC referral is undoubtedly associated with a reduction in hospital deaths, and this has clear implications for practitioners, who are often the gatekeepers of these services, as well as policy makers who are able to encourage referrals at a national level. What is unclear, however, is whether SPC referrals instigate discussions about preferred place of care and death, and the possibility of home/hospice death, or whether the patient has decided that their preferred place of care and death is home/hospice, and the referral was made to the service to facilitate this. Nonetheless, home deaths are clearly more likely to occur in patients with SPC referrals, and so, this information is important when considering how best to achieve preferred place of death when a patient and their family decides that this is not hospital.

Unanswered questions and future research {#s4d}
----------------------------------------

Haematological malignancies are complex, and our population-based patient cohort is now generating evidence which is facilitating a better understanding of palliative and end-of-life care in these diseases. We observed a high rate of SPC referrals, but this does not mean that patients who were not referred had unmet needs; it is possible that these patients did not have particularly complex problems that required involvement from SPC services, and so, were managed solely by the clinical haematology team in the hospital or by general practitioners and district nurses in the primary care setting. Conducting similar studies in different geographical areas would be useful to further assess variations in practice. Comparing our results with a cohort examining non-haematological cancers would also promote understanding of the differences between diseases. Further research addressing the reasons for SPC referral and non-referral, and differences in the preferred and actual place of death in patients with haematological malignancies is also relevant.

Conclusions {#s5}
===========

We have reported evidence of integration between haematology and SPC services, with more referrals among myeloma patients compared to those with AML or DLBCL. We found compelling indications that referral to SPC services was closely associated with death at home, although whether this is a direct result of SPC involvement cannot be determined. Increased integration between clinical haematologists and palliative care specialists may improve end-of-life planning for patients and, particularly, the facilitation of home death when this is the preferred place, even if the disease trajectory mitigates against this for many.
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